Cathepsin S is highly expressed in various cancer cells, and it has protumoral effects, including promotion of migration, invasion, and neovascularization. In this study, we show that inhibition of cathepsin S could sensitize cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis.
Results:
An inhibitor of cathepsin S (Z-FL-COCHO; ZFL) markedly induced apoptosis in human renal cancer cells treated with TRAIL. In contrast, combined treatment with ZFL and TRAIL had no effect on normal cells. ZFL downregulated Bcl-2 expression at the transcriptional level in a p53-dependent manner, and overexpression of Bcl-2 also markedly blocked apoptosis induced by combined treatment with ZFL and TRAIL. In addition, ZFL induced downregulation of c-FLIP, and overexpression of c-FLIP blocked the apoptosis induced by ZFL plus TRAIL. Moreover, ZFL increased the expression of Cbl, an E3 ligase of c-FLIP, in a p53-dependent manner, and knockdown of Cbl markedly prevented c-FLIP downregulation and the apoptosis induced by ZFL plus TRAIL. Interestingly, ZFL induced p53 expression via production of mitochondrial reactive oxygen species (ROS). We also demonstrated that downregulation of cathepsin S by small interfering RNA sensitized TRAIL-mediated apoptosis in Caki cells.
Innovation:
These results reveal the importance of cathepsin S on resistance against TRAIL, and inhibition of cathepsin S activity plays a crucial role in TRAIL-mediated cell death of cancer cells.
Conclusion:
Our results indicated that inhibition of cathepsin S stimulates TRAIL-induced apoptosis through downregulation of Bcl-2 and Cbl-mediated c-FLIP by ROS-mediated p53 expression. Antioxid. Redox Signal. 27, 215–233.
Bourgarel-ReyV, SavryA, HuaG, CarreM, BressinC, ChaconC, ImbertJ, BraguerD, and BarraY. Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Biochem Pharmacol, 78: 1148–1156, 2009.
3.
ChangL, KamataH, SolinasG, LuoJL, MaedaS, VenuprasadK, LiuYC, and KarinM. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell, 124: 601–613, 2006.
4.
ChenKL, ChangWS, CheungCH, LinCC, HuangCC, YangYN, KuoCP, KuoCC, ChangYH, LiuKJ, WuCM, and ChangJY. Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Lett, 317: 89–98, 2012.
5.
DriessenC, BryantRA, Lennon-DumenilAM, VilladangosJA, BryantPW, ShiGP, ChapmanHA, and PloeghHL. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J Cell Biol, 147: 775–790, 1999.
6.
FernandezPL, FarreX, NadalA, FernandezE, PeiroN, SloaneBF, ShiGP, ChapmanHA, CampoE, and CardesaA. Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer, 95: 51–55, 2001.
7.
FlanneryT, GibsonD, MirakhurM, McQuaidS, GreenanC, TrimbleA, WalkerB, McCormickD, and JohnstonPG. The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol, 163: 175–182, 2003.
8.
FlanneryT, McQuaidS, McGoohanC, McConnellRS, McGregorG, MirakhurM, HamiltonP, DiamondJ, CranG, WalkerB, ScottC, MartinL, EllisonD, PatelC, NicholsonC, MendelowD, McCormickD, and JohnstonPG. Cathepsin S expression: an independent prognostic factor in glioblastoma tumours—A pilot study. Int J Cancer, 119: 854–860, 2006.
9.
FukazawaT, FujiwaraT, UnoF, TeraishiF, KadowakiY, ItoshimaT, TakataY, KagawaS, RothJA, TschoppJ, and TanakaN. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene, 20: 5225–5231, 2001.
10.
GieffersC, KlugeM, MerzC, SykoraJ, ThiemannM, SchaalR, FischerC, BranschadelM, AbhariBA, HohenbergerP, FuldaS, FrickeH, and HillO. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther, 12: 2735–2747, 2013.
11.
GrollM and HuberR. Substrate access and processing by the 20S proteasome core particle. Int J Biochem Cell Biol, 35: 606–616, 2003.
12.
GuicciardiME, LeistM, and GoresGJ. Lysosomes in cell death. Oncogene, 23: 2881–2890, 2004.
13.
GumzML, ZouH, KreinestPA, ChildsAC, BelmonteLS, LeGrandSN, WuKJ, LuxonBA, SinhaM, ParkerAS, SunLZ, AhlquistDA, WoodCG, and CoplandJA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res, 13: 4740–4749, 2007.
14.
HiedaN, TokiY, SugiyamaS, ItoT, SatakeT, and OzawaT. Prostaglandin I2 analogue and propranolol prevent ischaemia induced mitochondrial dysfunction through the stabilisation of lysosomal membranes. Cardiovasc Res, 22: 219–225, 1988.
15.
HuangCC, ChenKL, CheungCH, and ChangJY. Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. Free Radic Biol Med, 65: 1473–1486, 2013.
16.
JiangF, ZhangY, and DustingGJ. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev, 63: 218–242, 2011.
17.
JinZ, McDonaldER3rd, DickerDT, and El-DeiryWS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem, 279: 35829–35839, 2004.
18.
KelleySK, HarrisLA, XieD, DeforgeL, TotpalK, BussiereJ, and FoxJA. Preclinical studies to predict the disposition of Apo2 L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther, 299: 31–38, 2001.
19.
KellyMM, HoelBD, and Voelkel-JohnsonC. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther, 1: 520–527, 2002.
20.
KimJH, KimEL, LeeYK, ParkCB, KimBW, WangHJ, YoonCH, LeeSJ, and YoonG. Decreased lactate dehydrogenase B expression enhances claudin 1-mediated hepatoma cell invasiveness via mitochondrial defects. Exp Cell Res, 317: 1108–1118, 2011.
21.
MiyashitaT, HarigaiM, HanadaM, and ReedJC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res, 54: 3131–3135, 1994.
22.
MohamedMM and SloaneBF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer, 6: 764–775, 2006.
23.
NgCP, Zisman A and BonavidaB. Synergy is achieved by complementation with Apo2 L/TRAIL and actinomycin D in Apo2 L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate, 53: 286–299, 2002.
24.
NylandstedJ, Gyrd-HansenM, DanielewiczA, FehrenbacherN, LademannU, Hoyer-HansenM, WeberE, MulthoffG, RohdeM, and JaattelaM. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med, 200: 425–435, 2004.
25.
PanL, LiY, JiaL, QinY, QiG, ChengJ, QiY, LiH, and DuJ. Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation. PLoS One, 7: e35315, 2012.
26.
PetermannI, MayerC, StypmannJ, BiniossekML, TobinDJ, EngelenMA, DandekarT, GruneT, SchildL, PetersC, and ReinheckelT. Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. FASEB J, 20: 1266–1268, 2006.
27.
PlugerEB, BoesM, AlfonsoC, SchroterCJ, KalbacherH, PloeghHL, and DriessenC. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol, 32: 467–476, 2002.
28.
RigouletM, YoboueED, and DevinA. Mitochondrial ROS generation and its regulation: mechanisms involved in H(2)O(2) signaling. Antioxid Redox Signal, 14: 459–468, 2011.
29.
SeoHR, BaeS, and LeeYS. Radiation-induced cathepsin S is involved in radioresistance. Int J Cancer, 124: 1794–1801, 2009.
30.
ShiGP, MungerJS, MearaJP, RichDH, and ChapmanHA. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem, 267: 7258–7262, 1992.
31.
ShiGP, VilladangosJA, DranoffG, SmallC, GuL, HaleyKJ, RieseR, PloeghHL, and ChapmanHA. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity, 10: 197–206, 1999.
32.
ShiGP, WebbAC, FosterKE, KnollJH, LemereCA, MungerJS, and ChapmanHA. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem, 269: 11530–11536, 1994.
33.
TallaridaRJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther, 298: 865–872, 2001.
34.
TsukubaT, YanagawaM, KadowakiT, TakiiR, OkamotoY, SakaiE, OkamotoK, and YamamotoK. Cathepsin E deficiency impairs autophagic proteolysis in macrophages. PLoS One, 8: e82415, 2013.
WalczakH, BouchonA, StahlH, and KrammerPH. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res, 60: 3051–3057, 2000.
37.
WangX, XiongL, YuG, LiD, PengT, LuoD, and XuJ. Cathepsin S silencing induces apoptosis of human hepatocellular carcinoma cells. Am J Transl Res, 7: 100–110, 2015.
38.
WooSM, MinKJ, and KwonTK. Calyculin A causes sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by ROS-mediated down-regulation of cellular FLICE-inhibiting protein (c-FLIP) and by enhancing death receptor 4 mRNA stabilization. Apoptosis, 17: 1223–1234, 2012.
39.
WuY, MehewJW, HeckmanCA, ArcinasM, and BoxerLM. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene, 20: 240–251, 2001.
40.
XuJ, LiD, KeZ, LiuR, MaubachG, and ZhuoL. Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. Mol Med Rep, 2: 713–718, 2009.
41.
ZengXC, BhasinS, WuX, LeeJG, MaffiS, NicholsCJ, LeeKJ, TaylorJP, GreeneLE, and EisenbergE. Hsp70 dynamics in vivo: effect of heat shock and protein aggregation. J Cell Sci, 117: 4991–5000, 2004.
42.
ZhangL, WangH, XuJ, ZhuJ, and DingK. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways. Toxicol Lett, 228: 248–259, 2014.
43.
ZhangY and ZhangB. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res, 6: 1861–1871, 2008.
44.
ZhaoL, YueP, KhuriFR, and SunSY. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer Res, 73: 1946–1957, 2013.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
